

References

- Aime S, Frullano L and Geninatti Crich S. (2002). Compartmentalization of a gadolinium complex in the apoferritin cavity: a route to obtain high relaxivity contrast agents for magnetic resonance imaging. *Angew Chem Int Ed Engl*, 41, 1017-1019.
- Artemov D. (2003). Molecular magnetic resonance imaging with targeted contrast agents. *J Cell Biochem.*, 90, 518-524.
- Artemov D, Mori N, Okollie B and Bhujwalla ZM. (2003). MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. *Magn Reson Med.*, 49, 403-408.
- Başar I, Ayhan A, Bircan K, Ergen A and Taşar C. (1991). Transferrin receptor activity as a marker in transitional cell carcinoma of the bladder. *Br J Urol.*, 67, 165-168.
- Boudreau RJ, Frick MP, Levey RM, Lund G, Sirr SA and Loken MK. (1986). The preliminary evaluation of Mn DTPA as a potential contrast agent for nuclear magnetic resonance imaging. *Am J Physiol Imaging.*, 1, 19-25.
- Caravan PJ, Ellison J, McMurry J and Lauffer RB. (1999). Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. *Chem Rev.*, 99, 2293–2352.
- Colet JM, Piérart C, Seghi F, Gabric I and Muller RN. (1998). Intravascular and intracellular hepatic relaxivities of superparamagnetic particles: an isolated and perfused organ pharmacokinetics study. *J Magn Reson.*, 134, 199–205.
- Davies JA, Dutremez SG, Hockensmith CM, Keck R, Richardson N, Selman S, Smith DA, Ulmer CW, Wheatley LS and Zeiss J. (1999). Iron-based second-sphere contrast agents for magnetic resonance imaging: development of a model system and evaluation of iron (III) tris (tironate) complex in rats. *Acad Radiol.*, 3, 936–945.
- Dechsupa S, Kothan S, Vergote J, Leger G, Martineau A, Berangeo S, Kosanlavit R, Moretti JL and Mankhetkorn S. (2007). Quercetin, Siamois1 and Siamois2 induce apoptosis in human breast cancer MDA-mB-435 cells xenograft in vivo. *Cancer Biol Ther.*, 6, 56-61.
- Dechsupa N, Tungjai M, Suttana W, Martinea A, Beranger S, Prarom V, Kothan S, Gunphairoh R, Moretti JL and Mankhetkorn S. (2007). In vitro and In vivo assessment of cancer cell response to flavonoids by using molecular imaging techniques. *Asia – SFRR-Asia*, 21-29.

Ebert SN, Taylor DG, Nguyen HL, Kodack DP, Beyers RJ, Xu Y, Yang Z and French BA. (2007). Noninvasive tracking of cardiac embryonic stem cells *in vivo* using magnetic resonance imaging techniques. *Stem Cells.*, 25, 2936-2944.

Geninatti Crich S, Barge A, Battistini E, Cabella C, Coluccia S, Longo D, Mainero V, Tarone G and Aime S. (2005). Magnetic resonance imaging visualization of targeted cells by the internalization of supramolecular adducts formed between avidin and biotinylated Gd³⁺ chelates. *J Biol Inorg Chem.*, 10, 78-86.

Giesel FL, Stroick M, Griebe M, Tröster H, von der Lieth CW, Requardt M, Rius M, Essig M, Kauczor HU, Hennerici MG and Fatar M. (2006). Gadofluorine m uptake in stem cells as a new magnetic resonance imaging tracking method: an *in vitro* and *in vivo* study. *Invest Radiol.*, 41, 868-873.

Hallaway PE, Eaton JW, Panter SS and Hedlund BE. (1989). Modulation of desferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. *Proc. Natl. Acad. Sci.*, 86, 10108-10112.

Homan R and Eisenberg M. (1985). A fluorescence quenching technique for the measurement of paramagnetic ion concentrations at the membrane/water interface. Intrinsic and X537A-mediated cobalt fluxes across lipid bilayer membranes. *Biochim Biophys Acta.*, 812, 485-492.

Jacobs A and Chang Ting W. (1980). Iron chelation with oral deferoxamine. *Lancet.*, 794.

Kövér F, Schwarcz A, Pál J, Bogner P, Vajna T, Vadon G and Dóczi T. (2004). Fast method for longitudinal relaxation time and water content mapping of the human brain on a clinical MR scanner. *Acta Neurochir (Wien).*, 146, 1341-1346.

Kothan S. (2008). Molecular Imaging of cancer cell response to chemotherapeutic drugs emphasized on P-glycoprotein function. *First Annual Symposium on Molecular Imaging*. Thailand, 79-84.

Kothan S, Dechsupa S, Leger G, Moretti JL, Vergote J and Mankhetkorn S. (2004). Spontaneous mitochondrial membrane potential change during apoptotic induction by quercetin in K562 and K562/adr cells. *Can J Physiol Pharmacol.*, 82, 1084-1090.

Kupka T, Dziegielewski JO, Pasterna G and Małecki JG. (1992). Copper-D-penicillamine complex as potential contrast agent for MRI. *Magn Reson Imaging.*, 10, 855-858.

Lauffer RB. (1987). Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. *Chem Rev.*, 87, 901-927.

Laurent S, Vander Elst L, Fu Y and Muller RN. (2004). Synthesis and physicochemical characterization of Gd-DTPA-B(sLex)A, a new MRI contrast agent targeted to inflammation. *Bioconjug Chem.*, 15, 99-103.

Loetchutinat C, Kothan S, Dechsупha S, Meesungneon J, Jay-Cerin JP and Mankhetkorn S. (2005). Spectrofluorometric determination of intracellular levels of reactive oxygen species in drug-sensitive and drug-resistant cancer cells using 2',7'-dichlorofluorescein diacetate assay. *Radiation Physics and Chemistry*, 72, 323-331.

Mankhetkorn S, Kothan S, Dechsупha N, Loetchutinat C, Tungjai M, Jaruchainiwat S, Kantapan J, Uttaracheva AU, Suttho D, Sintubual S and Gunpairoh R. (2008). Molecular Imaging of small animal bearing human cancer cells. *First Annual Symposium on Molecular Imaging, Chiangmai, Thailand.*; 63-69.

Recht L, Torres CO, Smith TW, Raso V and Griffin TW. (1990). Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. *J Neurosurg.*, 72, 941-945.

Reungpatthanaphong P and Mankhetkorn S. (2002). Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. *Biol Pharm Bull.*, 25, 1555-1561.

Reungpatthanaphong P, Dechsупha S, Meesungnoen J, Loetchutinat C and Mankhetkorn S. (2003). Rhodamine B as a mitochondrial probe for measurement and monitoring of mitochondrial membrane potential in drug-sensitive and -resistant cells. *J Biochem Biophys Methods.*, 57, 1-16.

Richardson N, Davies J and Radüchel B. (1999). Iron (III)-based contrast agents for magnetic resonance imaging. *Polyhedron.*, 18, 2457-2482.

Shindelman JE, Ortmeyer AE and Sussman HH. (1981). Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. *Int J Cancer.*, 27, 329-334.

Sibmooh N, Udomsangpetch R, Kujoa A, Chanharaksri U, Mankhetkorn S. (2001). Redox reaction of artemisinin with ferrous and ferric ions in aqueous buffer. *Chem Pharm Bull (Tokyo)*, 49, 1541-1546.

Sutherland R, Delia D, Schneider C, Newman R, Kemshead J and Greaves M. (1981). Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. *Proc Natl Acad Sci U S A.*, 78, 4515-4519.

Suttana W, Dechsupa N, Kothan S and Mankhetkorn S. (2007). Neuclear cytoplasmic and intralysosomal compartments staining of human leucocytes using AO and determined by flow cytometer. *RGJ- PH.D. Congress VIII*. Thailand.

Trowbridge IS and Omary MB. (1981). Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. *Proc Natl Acad Sci U S A.*, 78, 3039-3043.

Udomuttaracheva, A; Dechsupa, N; Kothan, S. (2007). Non-invasive spectrofluorometric and flow cytometric monitoring the interaction of Fe(III)-Desferroxamine Complex in peripheral blood mononucleated cell: Measurements of ROSi, m and pHv. *Graduate Student Academic day (AMS CMU)* Thailand, 41-43.

Udomuttaracheva, A; Suttana, W; Dechsupa, N; Kothan, S. (2008). Monitoring the interaction of Fe(III)-desferoxamine complex in peripheral blood mononucleated cells by spectrophotometry, flow cytometry and in Wistar rat by magnetic resonance imaging. *First Annual Symposium on Molecular Imaging*. Thailand, 85-89.

Wei JJ, Wang RZ, Lu JJ, Wang Y, Fan XT, Feng F, Ma WB, Yang Y, Li GL, Dou WC, Jin ZY and Kong YG. (2007). In vivo tracking of bone marrow mesenchymal stem cells labeled with superparamagnetic iron oxide after cerebral ischemia in rats by magnetic resonance imaging. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao.*, 29, 73-77.